Navigation Links
Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
Date:3/4/2016

CAMBRIDGE, Mass., March 4, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing new treatments for serious cardiometabolic diseases, today announced that management will present a company overview at the Cowen and Company 36th Annual Health Care Conference at 2:30 p.m. ET on Tuesday, March 8, 2016 in Boston, MA.

A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website.  The replay will be available within 48 hours and will be archived for a limited time.

ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders.  Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea has a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's drug pipeline includes novel antisense drugs designed to address a number of lipid risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a).  Akcea's most advanced program, volanesorsen, is in Phase 3 development to treat patients with ultra-orphan lipid disorders that are characterized by extremely high triglycerides and apoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL).  Akcea is located in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com.

ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases.  Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development.  Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy.  Ionis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Ionis is available at www.ionispharma.com.

FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis Pharmaceuticals Inc. and its wholly owned subsidiary, Akcea Therapeutics, Inc.  Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2015,which is on file with the SEC.  Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc.  Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. 

Logo - http://photos.prnewswire.com/prnh/20160118/323100LOGO

Logo - http://photos.prnewswire.com/prnh/20151221/317736LOGO

 


'/>"/>
SOURCE Ionis Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Akcea Therapeutics Appoints Louis St. L. ODea as Chief Medical Officer
2. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
3. Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
4. Webcast Alert: Akcea Therapeutics Conference Call
5. Chrono Therapeutics Smoking Cessation Technology Demonstrates Significant Reduction in Nicotine Cravings
6. Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business Results
7. Nektar Therapeutics to Present at Cowen and Companys 36th Annual Health Care Conference in Boston, MA
8. Cryoport Supports ImmunoCellular Therapeutics 120-Site Phase III Clinical Trial With Cold Chain Logistics
9. Immune Therapeutics, Inc., Appoints Two New Board Members
10. Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer
11. Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... 11, 2019 , ... Bloodstream infections (BSI) leading to sepsis ... may not receive the most targeted therapy in time because traditional microbiological methods ... pathogens has shown improvement in patient outcomes, but not all molecular panels have ...
(Date:9/11/2019)... , ... September 11, 2019 , ... ... headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – ... an oral and maxillofacial surgery practice with three locations in the Atlanta area. ...
(Date:9/11/2019)... ... 11, 2019 , ... With recent regulatory changes to state ... big pharma, nutraceutical manufacturers, food companies, and retailers. , Chronic CBD users represent ... to rise as access to hemp-derived CBD food products increases. In preclinical studies, ...
Breaking Medicine Technology:
(Date:9/17/2019)... , ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has hosted an annual ... by cancer. The event, entitled “Drive Out Cancer,” entails that for every vehicle purchased from ... Foundation. As the event lasts for 50 days, it has also been referred to as, ...
(Date:9/17/2019)... ... September 17, 2019 , ... National University has teamed ... Heart Association (AHA)-San Diego Chapter to raise awareness of heart health. Meb will ... September 21 in Balboa Park alongside National University System Chancellor and AHA Heart ...
(Date:9/17/2019)... ... September 17, 2019 , ... Encouraging a spirit of partnership ... Vice President of Insurance Plan Management for Dental Care Alliance, the 2019 Don ... at their annual conference, CONVERGE 2019, in Orlando. This award commends exemplary service ...
(Date:9/17/2019)... ... 17, 2019 , ... Since the registration of the NociScan ... in the US, Nocimed has been marketing its unique technology to healthcare clinicians ... MRI equipment to perform MR spectroscopy, NociScan detects the presence of chemical biomarkers ...
(Date:9/17/2019)... Ga. (PRWEB) , ... September 17, 2019 , ... ... social responsibility initiative contributing to the long-term health of canines – specifically golden ... of all Golden Retrievers will die from cancer – one out of five ...
Breaking Medicine News(10 mins):